Cantor Fitzgerald analyst Charles Duncan maintains $Axsome Therapeutics (AXSM.US)$ with a buy rating, and adjusts the target price from $107 to $121.
According to TipRanks data, the analyst has a success rate of 51.4% and a total average return of 24.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Axsome Therapeutics (AXSM.US)$'s main analysts recently are as follows:
Following a quarterly update that surpassed revenue expectations and provided promising pipeline developments, an analyst has acknowledged the clarification regarding the timeline of two concurrent Phase 3 Auvelity ADA trials. The simultaneous readouts expected in the fourth quarter clarify the forthcoming catalyst events. It is believed that achieving success in one of the two ADA trials may be sufficient to dispel any lingering concerns over regulatory outlooks for the crucial label expansion.
The third quarter of 2024 was notable for Axsome Therapeutics, mainly driven by a promising increase in Auvelity sales. The company remains a top selection due to the belief that it possesses the most compelling set of potential market influencers within the coverage universe through the end of the fourth quarter of 2024.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
坎托·菲茨杰拉德分析師Charles Duncan維持$Axsome Therapeutics (AXSM.US)$買入評級，並將目標價從107美元上調至121美元。
根據TipRanks數據顯示，該分析師近一年總勝率為51.4%，總平均回報率為24.3%。
此外，綜合報道，$Axsome Therapeutics (AXSM.US)$近期主要分析師觀點如下：
在一次超過營業收入預期並提供有希望的管道發展的季度更新之後，一位分析師承認了關於兩個同時進行的第三階段Auvelity ADA試驗時間表的澄清。預計在第四季度的同時結果澄清了即將到來的催化劑事件。人們相信，在兩個ADA試驗中取得成功可能足以消除對這一關鍵標籤擴展的監管前景的任何持續擔憂。
2024年第三季度對axsome therapeutics而言意義重大，主要受益於Auvelity銷售的良好增長。由於公司被認爲在2024年第四季度結束時擁有最具吸引力的一系列潛在市場影響因素，因此仍然是頂級選擇。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
